SPARC
vs
BSE Sensex 30
Over the past 12 months, SPARC has underperformed BSE Sensex 30, delivering a return of -33% compared to the BSE Sensex 30's 6% growth.
Stocks Performance
SPARC vs BSE Sensex 30
Performance Gap
SPARC vs BSE Sensex 30
Performance By Year
SPARC vs BSE Sensex 30
Sun Pharma Advanced Research Co Ltd
Glance View
Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-07-18. The firm is engaged in the business of research and development (R&D) of pharmaceutical products to meet unmet medical needs in the areas of oncology, neurodegeneration and immunology. The company develops new chemical entities (NCE), new biological entities (NDDS) and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its NDDS includes Wrap Matrix technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology, which is useful to develop controlled-release tablets. The firm has developed Elepsia XR, using Wrap Matrix technology. Lipexelle technology for ophthalmic formulations. The company has developed Xelpros, a BAK-free latanoprost eye drops developed using Lipexelle technology. Xelpros is commercialized by the Company’s partner in the United States. The company developed PDP-716 eye drops for the treatment of glaucoma based on its TearAct technology.